{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:19Z","timestamp":1760143459777,"version":"build-2065373602"},"reference-count":64,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hospital Cl\u00ednic de Barcelona","award":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"],"award-info":[{"award-number":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"]}]},{"name":"Convocat\u00f2ria d\u2019Intensificaci\u00f3 Interna per als professionals de l\u2019HCB 2023 (MDB)","award":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"],"award-info":[{"award-number":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"],"award-info":[{"award-number":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union","award":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"],"award-info":[{"award-number":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"]}]},{"name":"Fundaci\u00f3 la Marat\u00f3 TV3 sobre C\u00e0ncer","award":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"],"award-info":[{"award-number":["FIS PI19\/01476","FIS PI22\/01660","201 201930-31"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Non-acute myeloid neoplasms (MNs) with NPM1 mutations (NPM1mut-MNs) pose a diagnostic and therapeutic dilemma, primarily manifesting as chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS). The classification and treatment approach for these conditions as acute myeloid leukemia (AML) are debated. We describe eight cases of atypical NPM1mut-MNs from our institution and review the literature. We include a rare case of concurrent prostate carcinoma and MN consistent with chronic eosinophilic leukemia, progressing to myeloid sarcoma of the skin. Of the remaining seven cases, five were CMML and two were MDS. NPM1 mutations occur in 3\u20135% of CMML and 1\u20136% of MDS, with an increased likelihood of rapid evolution to AML. Their influence on disease progression varies, and their prognostic significance in non-acute MNs is less established than in AML. Non-acute MNs with NPM1 mutations may display an aggressive clinical course, emphasizing the need for a comprehensive diagnosis integrating clinical and biological data. Tailoring patient management on an individualized basis, favoring intensive treatment aligned with AML protocols, is crucial, regardless of blast percentage. Research on the impact of NPM1 mutations in non-acute myeloid neoplasms is ongoing, requiring challenging prospective studies with substantial patient cohorts and extended follow-up periods for validation.<\/jats:p>","DOI":"10.3390\/cancers16040705","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T06:12:58Z","timestamp":1707286378000},"page":"705","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Infrequent Presentations of Chronic NPM1-Mutated Myeloid Neoplasms: Clinicopathological Features of Eight Cases from a Single Institution and Review of the Literature"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-4665","authenticated-orcid":false,"given":"Sandra","family":"Casta\u00f1o-D\u00edez","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medical School, University of Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-0929","authenticated-orcid":false,"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Hematopathology Section, Servei d\u2019Anatomia Patol\u00f2gica, CDB, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-0178","authenticated-orcid":false,"given":"M\u00f2nica","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Hematopathology Section, Servei d\u2019Anatomia Patol\u00f2gica, CDB, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Isabel","family":"P\u00e9rez-Valencia","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"G\u00f3mez-N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Hospital Parc Tauli Sabadell, 08208 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-8484","authenticated-orcid":false,"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Hematopathology Section, Servei d\u2019Anatomia Patol\u00f2gica, CDB, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medical School, University of Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Rozman","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Hematopathology Section, Servei d\u2019Anatomia Patol\u00f2gica, CDB, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1053\/j.semdp.2023.04.005","article-title":"Genomics of myelodysplastic\/myeloproliferative neoplasm","volume":"40","author":"Patwardhan","year":"2023","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00428-022-03417-1","article-title":"The International Consensus Classification of myelodysplastic syndromes and related entities","volume":"482","author":"Hasserjian","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Sasaki","year":"2019","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/ijms21238975","article-title":"NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?","volume":"21","author":"Forghieri","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00428-022-03465-7","article-title":"Advances in myelodysplastic\/myeloproliferative neoplasms","volume":"482","author":"Prakash","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2040620719854596","DOI":"10.1177\/2040620719854596","article-title":"Chronic myelomonocytic leukemia associated with myeloid sarcomas and NPM1 mutation: A case report and literature review","volume":"10","author":"Matanes","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ajh.26989","article-title":"NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions","volume":"98","author":"Falini","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1002\/ajh.26946","article-title":"The NPM1 mutant defines AML irrespective of blast count","volume":"98","author":"Falini","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.pathol.2022.10.009","article-title":"Acute myeloid leukaemia with NPM1 mutation: No longer having an absolute blast (count)","volume":"55","author":"Zhang","year":"2023","journal-title":"Pathology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: A fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/cncr.34119","article-title":"Time to blur the blast boundaries","volume":"128","author":"DiNardo","year":"2022","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/bjh.16628","article-title":"NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy","volume":"189","author":"Wu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chin, L., Wong, C.Y.G., and Gill, H. (2023). Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043161"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1182\/blood-2023-173311","article-title":"Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations (NPM1, FLT3 or CEBPA) Identify a High-Risk CMML Group Independent of Molecular-Cpss","volume":"142","author":"Zugasti","year":"2023","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Casta\u00f1o-D\u00edez, S., L\u00f3pez-Guerra, M., Bosch-Casta\u00f1eda, C., Bataller, A., Charry, P., Esteban, D., Guijarro, F., Jim\u00e9nez-Vicente, C., Castillo-Gir\u00f3n, C., and Cortes, A. (2022). Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes. Cancers, 14.","DOI":"10.3390\/cancers14174107"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrc1885","article-title":"Nucleophosmin and cancer","volume":"6","author":"Grisendi","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/leu.2017.30","article-title":"Biological and clinical consequences of NPM1 mutations in AML","volume":"31","author":"Heath","year":"2017","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc + AML): Biologic and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-05-2378","article-title":"Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant","volume":"66","author":"Colombo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: From bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1083\/jcb.200711040","article-title":"Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma","volume":"182","author":"Bonetti","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ncb1764","article-title":"A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth","volume":"10","author":"Wanzel","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1172\/JCI97117","article-title":"Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates","volume":"128","author":"Gu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jmb.2008.02.055","article-title":"Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription","volume":"378","author":"Gurumurthy","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 Maintains the Leukemic State through HOX Expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.23139","article-title":"The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms","volume":"62","author":"Kaseb","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3109\/10428194.2015.1026900","article-title":"NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic\/myeloproliferative neoplasms","volume":"56","author":"Forghieri","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s12185-017-2243-z","article-title":"CMML: Clinical and molecular aspects","volume":"105","author":"Itzykson","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated with Hypomethylating Agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1038\/bcj.2014.90","article-title":"Chronic myelomonocytic leukemia in younger patients: Molecular and cytogenetic predictors of survival and treatment outcome","volume":"5","author":"Patnaik","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Shou, L.H., Cao, D., Dong, X.H., Fang, Q., Wu, Y., Zhang, Y., Fei, J.P., and Xu, B.L. (2017). Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171608"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106190","DOI":"10.1016\/j.leukres.2019.106190","article-title":"Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia","volume":"84","author":"Hwang","year":"2019","journal-title":"Leuk Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2006.06081.x","article-title":"C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders","volume":"133","author":"Caudill","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_45","first-page":"1147","article-title":"Mutations and promoter methylation status of NPM1 in myeloproliferative disorders","volume":"91","author":"Oki","year":"2006","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/modpathol.2012.218","article-title":"Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia","volume":"26","author":"Courville","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ejh.12549","article-title":"Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation","volume":"96","author":"Peng","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1002\/ajh.24861","article-title":"Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"92","author":"Vallapureddy","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3324\/haematol.2010.021808","article-title":"Transcription factor mutations in myelodysplastic\/myeloproliferative neoplasms","volume":"95","author":"Ernst","year":"2010","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-022-00284-z","article-title":"Mutational landscape of chronic myelomonocytic leukemia in Chinese patients","volume":"11","author":"Nie","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2006.03.013","article-title":"NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype","volume":"31","author":"Zhang","year":"2007","journal-title":"Leuk Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPEI9XU8PYBCIO","article-title":"FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia","volume":"135","author":"Bains","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nature03915","article-title":"Role of nucleophosmin in embryonic development and tumorigenesis","volume":"437","author":"Grisendi","year":"2005","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1182\/blood-2007-06-098251","article-title":"Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse","volume":"111","author":"Sportoletti","year":"2008","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Chou, S.H., Ko, B.S., Chiou, J.S., Hsu, Y.C., Tsai, M.H., Chiu, Y.C., Yu, I.S., Lin, S.W., Hou, H.A., and Kuo, Y.Y. (2012). A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049769"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2009-03-208587","article-title":"The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model","volume":"115","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2009-02-207225","article-title":"Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish","volume":"115","author":"Bolli","year":"2010","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/leu.2010.299","article-title":"Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms","volume":"25","author":"Schnittger","year":"2011","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Wang, M., He, N., Tian, T., Liu, L., Yu, S., and Ma, D. (2014). Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/485645"},{"key":"ref_61","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissue, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000085559","article-title":"Molecular Classification and Pathogenesis of Eosinophilic Disorders: 2005 Update","volume":"114","author":"Gotlib","year":"2005","journal-title":"Acta Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_64","first-page":"45","article-title":"A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia","volume":"9","author":"Hofmans","year":"2018","journal-title":"Leuk Res. Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/705\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:26Z","timestamp":1760104586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16040705"],"URL":"https:\/\/doi.org\/10.3390\/cancers16040705","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}